More On

The patent war over hepatitis C drugs

Big pharma companies are locked in a patent litigation battle over hepatitis C drugs

The patent wars in the high tech space get a lot of coverage, between lawsuits from so-called patent trolls to dustups between tech giants, there is rarely a shortage of news. But patent litigation in the pharma space is often a bit quieter, if only because it so often revolves around large drug makers suing companies that produce generic versions of certain medication.

But now, a battle over hepatitis C treatments has roped in several large drug manufacturers. The patent litigation stems from Gilead Sciences, which developed a hepatitis C treatment called Sovaldi. Now the company is going after three of its rivals: Merck, AbbVie and Roche. 

Senior Editor and Community Manager

author image

Rich Steeves

Richard P. Steeves is Senior Editor and Community Manager of InsideCounsel magazine, where he covers the intellectual property and compliance beats. Rich earned a B.A....

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.